Compare GDL & ICCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GDL | ICCC |
|---|---|---|
| Founded | 2006 | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 90.7M | 75.8M |
| IPO Year | N/A | 1995 |
| Metric | GDL | ICCC |
|---|---|---|
| Price | $8.49 | $10.21 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 6.6K | ★ 25.8K |
| Earning Date | 01-01-0001 | 05-15-2026 |
| Dividend Yield | ★ 6.02% | N/A |
| EPS Growth | N/A | ★ 53.85 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $26,493,169.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 51.64 |
| 52 Week Low | $8.19 | $4.52 |
| 52 Week High | $8.67 | $10.25 |
| Indicator | GDL | ICCC |
|---|---|---|
| Relative Strength Index (RSI) | 54.91 | 78.28 |
| Support Level | $8.39 | $5.85 |
| Resistance Level | $8.53 | N/A |
| Average True Range (ATR) | 0.05 | 0.45 |
| MACD | -0.00 | 0.10 |
| Stochastic Oscillator | 58.88 | 99.56 |
GDL Fund is a diversified closed-end management investment company. Its primary investment objective is to achieve absolute returns in various market conditions without excessive risk of capital. The fund seeks to achieve its objective by investing in merger arbitrage transactions and, to a lesser extent, in corporate reorganizations involving stubs, spin-offs, and liquidations.
ImmuCell Corp is an animal health biologics company focused on the development, manufacture, and commercialization of products intended to improve the survivability, health, and long-term performance of neonatal dairy and beef calves. Its product, First Defense, utilizes hyperimmunized bovine colostrum to provide pathogen-specific antibodies and other bioactive components. First Defense is designed to provide Immediate Immunity through orally delivered antibodies against the principal viral and bacterial causes of neonatal calf diarrhea (scours), including Escherichia coli (E.coli), bovine coronavirus, and bovine rotavirus. It has two operating segments: Scours and Mastitis. It derives the majority of the revenue from the Scours segment that consists of the First Defense product line.